Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?

Philipp Schriefer; Stefan Steurer; Hartwig Huland; Markus Graefen

Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?

Standard

Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy? / Schriefer, Philipp; Steurer, Stefan; Huland, Hartwig; Graefen, Markus.

In: J CLIN ONCOL, Vol. 30, No. 32, 32, 2012, p. 341-344.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schriefer, P, Steurer, S, Huland, H & Graefen, M 2012, 'Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?', J CLIN ONCOL, vol. 30, no. 32, 32, pp. 341-344. <http://www.ncbi.nlm.nih.gov/pubmed/23032622?dopt=Citation>

APA

Schriefer, P., Steurer, S., Huland, H., & Graefen, M. (2012). Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy? J CLIN ONCOL, 30(32), 341-344. [32]. http://www.ncbi.nlm.nih.gov/pubmed/23032622?dopt=Citation

Vancouver

Schriefer P, Steurer S, Huland H, Graefen M. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy? J CLIN ONCOL. 2012;30(32):341-344. 32.

Bibtex

@article{d85426089c3341378ef5b93fca040ae6,

title = "Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?",

keywords = "Humans, Male, Aged, Middle Aged, Treatment Outcome, Predictive Value of Tests, Disease Progression, Fatal Outcome, Radiotherapy Dosage, Tomography, X-Ray Computed, Neoplasm Staging, Lymph Node Excision, Tumor Markers, Biological/*blood, Prostate-Specific Antigen/*blood, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Grading, Chemoradiotherapy, Biopsy/methods, *Prostatectomy/methods, Adenocarcinoma/chemistry/*diagnosis/immunology/pathology/therapy, Antigens, Surface/analysis, Bone Neoplasms/secondary, Glutamate Carboxypeptidase II/analysis, Liver Neoplasms/secondary, Lung Neoplasms/secondary, Neoplasm Recurrence, Local/chemistry/*diagnosis/immunology/therapy, Phosphopyruvate Hydratase/blood, Prostatic Neoplasms/chemistry/*diagnosis/immunology/pathology/therapy, Receptors, Androgen/analysis, Humans, Male, Aged, Middle Aged, Treatment Outcome, Predictive Value of Tests, Disease Progression, Fatal Outcome, Radiotherapy Dosage, Tomography, X-Ray Computed, Neoplasm Staging, Lymph Node Excision, Tumor Markers, Biological/*blood, Prostate-Specific Antigen/*blood, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Grading, Chemoradiotherapy, Biopsy/methods, *Prostatectomy/methods, Adenocarcinoma/chemistry/*diagnosis/immunology/pathology/therapy, Antigens, Surface/analysis, Bone Neoplasms/secondary, Glutamate Carboxypeptidase II/analysis, Liver Neoplasms/secondary, Lung Neoplasms/secondary, Neoplasm Recurrence, Local/chemistry/*diagnosis/immunology/therapy, Phosphopyruvate Hydratase/blood, Prostatic Neoplasms/chemistry/*diagnosis/immunology/pathology/therapy, Receptors, Androgen/analysis",

author = "Philipp Schriefer and Stefan Steurer and Hartwig Huland and Markus Graefen",

year = "2012",

language = "English",

volume = "30",

pages = "341--344",

journal = "J CLIN ONCOL",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "32",